Department of Biophysics, School of Medicine, Kahramanmaras Sütçü Imam University, Kahramanmaras, 46100, Turkey.
Fundam Clin Pharmacol. 2013 Apr;27(2):161-8. doi: 10.1111/j.1472-8206.2011.00998.x. Epub 2011 Oct 11.
Nothing is known about actions of levobupivacaine, a long-acting local anaesthetic belonging to the amino amide group, in diabetes-induced neuropathic pain conditions. In this study, we therefore investigated the possible antihyperalgesic and antiallodynic effects of levobupivacaine in diabetic animal model. Actions of systemically (intraperitoneal) or locally (intraplantar) administrated levobupivacaine on streptozotocin-induced diabetic rats with painful neuropathy were examined using a thermal plantar test and a dynamic plantar aesthesiometer. Effects of levobupivacaine were compared with those of a well-known amide local anaesthetic lidocaine. Levobupivacaine was more potent than lidocaine in all tests employed on diabetic rats. After intraperitoneal injections to diabetic rats, levobupivacaine, but not lidocaine, produced pronounced antihyperalgesic and antiallodynic effects. However, intraplantar administration of both levobupivacaine and lidocaine produced antihyperalgesic and antiallodynic action in diabetic rats. In contrast to the transient effects of lidocaine (30 min), antihyperalgesic and antiallodynic actions of levobupivacaine gradually disappeared within 120 min after intraplantar injections. Intraperitoneal or intraplantar administrations of levobupivacaine or lidocaine at the effective dose had no effect on any parameters in intact rats. Findings revealed that antiallodynic and antihyperalgesic potency of levobupivacaine was higher in comparison with that of lidocaine after their intraperitoneal or intraplantar administration to diabetic animals. Furthermore, locally administrated levobupivacaine has the greatest antihyperalgesic and antiallodynic actions in diabetic rats.
目前尚不清楚属于酰胺类的长效局部麻醉药左布比卡因在糖尿病性神经病理性疼痛情况下的作用。因此，在本研究中，我们研究了左布比卡因在糖尿病动物模型中的潜在抗痛觉过敏和抗感觉异常作用。使用热足底测试和动态足底触觉计检查了系统（腹腔内）或局部（足底内）给予左布比卡因对链脲佐菌素诱导的伴痛性神经病变糖尿病大鼠的可能抗hyperalgesic 和抗 allodynic 作用。将左布比卡因的作用与已知的酰胺局部麻醉药利多卡因的作用进行了比较。在所有用于糖尿病大鼠的测试中，左布比卡因均比利多卡因更有效。在糖尿病大鼠中腹腔内注射后，左布比卡因而不是利多卡因产生了明显的抗痛觉过敏和抗感觉异常作用。然而，在糖尿病大鼠中，左布比卡因和利多卡因的足底内给药均产生抗痛觉过敏和抗感觉异常作用。与利多卡因的短暂作用（30 分钟）相反，左布比卡因的抗痛觉过敏和抗感觉异常作用在足底内注射后 120 分钟内逐渐消失。在完整大鼠中，腹腔内或足底内给予左布比卡因或利多卡因的有效剂量对任何参数均无影响。研究结果表明，与腹腔内或足底内给予糖尿病动物时的利多卡因相比，左布比卡因的抗感觉异常和抗痛觉过敏作用更强。此外，局部给予左布比卡因在糖尿病大鼠中具有最大的抗痛觉过敏和抗感觉异常作用。
